{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T15:24:57Z","timestamp":1767108297700,"version":"3.37.3"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Guangdong Medical Science and Technology Research Fund","award":["A2014413"],"award-info":[{"award-number":["A2014413"]}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12985-016-0522-6","type":"journal-article","created":{"date-parts":[[2016,4,9]],"date-time":"2016-04-09T00:33:40Z","timestamp":1460162020000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Potential effects of telbivudine and entecavir on renal function: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"13","author":[{"given":"Xiaolu","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaohang","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhandong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caixia","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiulan","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianyong","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,4,9]]},"reference":[{"key":"522_CR1","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s12072-012-9365-4","volume":"6","author":"Y Liaw","year":"2012","unstructured":"Liaw Y, Kao J, Piratvisuth T, Chan HL, Chien RN, Liu CJ, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6:531\u201361.","journal-title":"Hepatol Int"},{"key":"522_CR2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2147\/PPA.S71510","volume":"9","author":"J Peng","year":"2015","unstructured":"Peng J, Yin J, Cai S, Yu T, Zhong C. Factors associated with adherence to nucleos(t)ide analogs in chronic hepatitis B patients: results from a 1-year follow-up study. Patient Prefer Adherence. 2015;9:41\u20135.","journal-title":"Patient Prefer Adherence"},{"key":"522_CR3","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1365-2893.2011.01494.x","volume":"19","author":"W Chotiyaputta","year":"2012","unstructured":"Chotiyaputta W, Hongthanakorn C, Oberhelman K, Fontana RJ, Licari T, Lok AS. Adherence to nucleos(t)ide analogues for chronic hepatitis B in clinical practice and correlation with virological breakthroughs. J Viral Hepat. 2012;19:205\u201312.","journal-title":"J Viral Hepat"},{"key":"522_CR4","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s12072-010-9163-9","volume":"4","author":"SH Ahn","year":"2010","unstructured":"Ahn SH, Chan HL, Chen PJ, Cheng J, Goenka MK, Hou J, et al. Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions. Hepatol Int. 2010;4:386\u201395.","journal-title":"Hepatol Int"},{"key":"522_CR5","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1038\/ajg.2009.200","volume":"104","author":"J Fung","year":"2009","unstructured":"Fung J, Lai CL, Tanaka Y, Mizokami M, Yuen J, Wong DK, et al. The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion. Am J Gastroenterol. 2009;104:1940\u20137.","journal-title":"Am J Gastroenterol"},{"key":"522_CR6","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","volume":"57","author":"EASL","year":"2012","unstructured":"EASL. Clinical Practice Guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167\u201385.","journal-title":"J Hepatol"},{"key":"522_CR7","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/jgh.12499","volume":"29","author":"J Fung","year":"2014","unstructured":"Fung J, Seto WK, Lai CL, Yuen MF. Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment. J Gastroenterol Hepatol. 2014;29:428\u201334.","journal-title":"J Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"522_CR8","doi-asserted-by":"crossref","first-page":"S147","DOI":"10.1016\/S0168-8278(11)60368-1","volume":"54","author":"K Deterding","year":"2011","unstructured":"Deterding K, Lampe N, Reijnders J, Manns MP, Janssen H, Zoulim F, et al. Prevalence and severity of kidney dysfunction in patients with chronic hepatitis B in Europe: data from the European Virgil Cohort. J Hepatol. 2011;54 Suppl 1:S147.","journal-title":"J Hepatol"},{"key":"522_CR9","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1053\/j.gastro.2013.09.031","volume":"146","author":"EJ Gane","year":"2014","unstructured":"Gane EJ, Deray G, Liaw YF, Lim SG, Lai CL, Rasenack J, et al. Telbivudine improves renal function in patients with chronic hepatitis B. Gastroenterology. 2014;146:138\u201346.","journal-title":"Gastroenterology"},{"issue":"Suppl 3","key":"522_CR10","doi-asserted-by":"crossref","first-page":"S164","DOI":"10.1016\/S1590-8658(11)60276-4","volume":"43","author":"P Lampertico","year":"2011","unstructured":"Lampertico P, Vigan\u00f2 M, Yurdaydin C, Idilman R, Buti M, Esteban R, et al. Effectiveness and safety of tenofovir disoproxil fumarate in field practice: a multicenter European cohort study of 737 patients with chronic hepatitis B. Dig Liver Dis. 2011;43 Suppl 3:S164.","journal-title":"Dig Liver Dis"},{"key":"522_CR11","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.cgh.2014.11.021","volume":"13","author":"V Mallet","year":"2015","unstructured":"Mallet V, Schwarzinger M, Vallet-Pichard A, Fontaine H, Corouge M, Sogni P, et al. Effect of nucleoside and nucleotide analogues on renal function in patients with chronic hepatitis B virus monoinfection. Clin Gastroenterol Hepatol. 2015;13:1181\u20138. e1.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"522_CR12","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s00535-013-0779-0","volume":"49","author":"M Tanaka","year":"2014","unstructured":"Tanaka M, Suzuki F, Seko Y, Hara T, Kawamura Y, Sezaki H, et al. Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B. J Gastroenterol. 2014;49:470\u201380.","journal-title":"J Gastroenterol"},{"key":"522_CR13","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1665-2681(19)30779-3","volume":"14","author":"H Jia","year":"2015","unstructured":"Jia H, Ding F, Chen J, Zhang Y, Xiang D, Lian J, et al. LAM add-on ADV combination therapy or ETV monotherapy for CHB patients with suboptimal response to ADV. Ann Hepatol. 2015;14:175\u201380.","journal-title":"Ann Hepatol"},{"key":"522_CR14","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/jvh.12229","volume":"22","author":"X Qi","year":"2015","unstructured":"Qi X, Wang JY, Mao RC, Zhang JM. Impact of nucleos(t)ide analogues on the estimated glomerular filtration rate in patients with chronic hepatitis B: a prospective cohort study in China. J Viral Hepat. 2015;22:46\u201354.","journal-title":"J Viral Hepat"},{"key":"522_CR15","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.3748\/wjg.v21.i12.3657","volume":"21","author":"HY Jia","year":"2015","unstructured":"Jia HY, Ding F, Chen JY, Lian JS, Zhang YM, Zeng LY, et al. Early kidney injury during long-term adefovir dipivoxil therapy for chronic hepatitis B. World J Gastroenterol. 2015;21:3657\u201362.","journal-title":"World J Gastroenterol"},{"key":"522_CR16","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/apt.13036","volume":"41","author":"S Koklu","year":"2015","unstructured":"Koklu S, Gulsen MT, Tuna Y, Koklu H, Yuksel O, Demir M, et al. Differences in nephrotoxicity risk and renal effects among anti-viral therapies against hepatitis B. Aliment Pharm Ther. 2015;41:310\u20139.","journal-title":"Aliment Pharm Ther"},{"key":"522_CR17","doi-asserted-by":"crossref","first-page":"e646","DOI":"10.1097\/MD.0000000000000646","volume":"94","author":"X Qi","year":"2015","unstructured":"Qi X, Wang J, Chen L, Huang Y, Qin Y, Mao R, et al. Impact of nucleos(t)ide analogue combination therapy on the estimated glomerular filtration rate in patients with chronic hepatitis B. Medicine (Baltimore). 2015;94:e646.","journal-title":"Medicine (Baltimore)"},{"key":"522_CR18","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177\u201388.","journal-title":"Control Clin Trials"},{"key":"522_CR19","first-page":"95","volume":"22","author":"MC Tsai","year":"2016","unstructured":"Tsai MC, Chen CH, Tseng PL, Hung CH, Chiu KW, Wang JH, et al. Comparison of renal safety and efficacy of telbivudine, entecavir and tenofovir treatment in chronic hepatitis B patient: real world experience. Clin Microbiol Infect. 2016;22:95. e1-7 [Epub 2015, Jun 5].","journal-title":"Clin Microbiol Infect"},{"key":"522_CR20","doi-asserted-by":"crossref","first-page":"776","DOI":"10.5009\/gnl14297","volume":"9","author":"S Lee","year":"2015","unstructured":"Lee S, Park JY, Song K, Kim DY, Kim BK, Kim SU, et al. Comparison of the effects of telbivudine and entecavir treatment on estimated glomerular filtration rate in patients with chronic hepatitis B. Gut Liver. 2015;9:776\u201383.","journal-title":"Gut Liver"},{"key":"522_CR21","doi-asserted-by":"crossref","first-page":"e15074","DOI":"10.5812\/hepatmon.15074","volume":"14","author":"KH Liang","year":"2014","unstructured":"Liang KH, Chen YC, Hsu CW, Chang ML, Yeh CT. Decrease of serum angiotensin converting enzyme levels upon telbivudine treatment for chronic hepatitis B virus infection and negative correlations between the enzyme levels and estimated glomerular filtration rates. Hepat Mon. 2014;14:e15074.","journal-title":"Hepat Mon"},{"key":"522_CR22","first-page":"11","volume":"52","author":"J Yan","year":"2012","unstructured":"Yan J, Han T. Impact of nucleoside analogues on glomerular filtration rate in patients with chronic hepatitis B. Shandong Med J. 2012;52:11\u20133.","journal-title":"Shandong Med J"},{"key":"522_CR23","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.jhep.2011.03.030","volume":"55","author":"S Mauss","year":"2011","unstructured":"Mauss S, Berger F, Filmann N, Hueppe D, Henke J, Hegener P, et al. Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B. J Hepatol. 2011;55:1235\u201340.","journal-title":"J Hepatol"},{"key":"522_CR24","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/hep.23044","volume":"50","author":"NB Ha","year":"2009","unstructured":"Ha NB, Ha NB, Garcia RT, Trinh HN, Vu AA, Nguyen HA, et al. Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. Hepatology. 2009;50:727\u201334.","journal-title":"Hepatology"},{"key":"522_CR25","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1111\/j.1440-1746.2008.05510.x","volume":"23","author":"SU Kim","year":"2008","unstructured":"Kim SU, Han KH, Nam CM, Park JY, Kim DY, Chon CY, et al. Natural history of hepatitis B virus-related cirrhotic patients hospitalized to control ascites. J Gastroenterol Hepatol. 2008;23:1722\u20137.","journal-title":"J Gastroenterol Hepatol"},{"key":"522_CR26","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1097\/00007890-199612270-00018","volume":"62","author":"RJ Brown","year":"1996","unstructured":"Brown RJ, Lombardero M, Lake JR. Outcome of patients with renal insufficiency undergoing liver or liver-kidney transplantation. Transplantation. 1996;62:1788\u201393.","journal-title":"Transplantation"},{"key":"522_CR27","first-page":"79","volume":"13","author":"DN Amarapurkar","year":"1994","unstructured":"Amarapurkar DN, Dhawan P, Kalro RH. Role of routine estimation of creatinine clearance in patients with liver cirrhosis. Indian J Gastroenterol. 1994;13:79\u201382.","journal-title":"Indian J Gastroenterol"},{"issue":"Suppl 2","key":"522_CR28","first-page":"S210","volume":"56","author":"P Marcellin","year":"2012","unstructured":"Marcellin P, Zoulim F, Causse X, H\u00e9zode C, Larrey D, Pageaux G, et al. Tenofovir DF treatment is safe and well tolerated in chronic hepatitis B (CHB) patients with baseline decreased glomerular filtration rate. J Hepatol. 2012;56 Suppl 2:S210.","journal-title":"J Hepatol"},{"key":"522_CR29","doi-asserted-by":"crossref","first-page":"945","DOI":"10.3851\/IMP2649","volume":"18","author":"DM Gracey","year":"2013","unstructured":"Gracey DM, Snelling P, McKenzie P, Strasser SI. Tenofovir-associated Fanconi syndrome in patients with chronic hepatitis B monoinfection. Antivir Ther. 2013;18:945\u20138.","journal-title":"Antivir Ther"},{"issue":"Suppl 1","key":"522_CR30","doi-asserted-by":"crossref","first-page":"S316","DOI":"10.1016\/S0168-8278(13)60779-5","volume":"58","author":"M Vigan\u00f2","year":"2013","unstructured":"Vigan\u00f2 M, Lampertico P, Mangia G, Soffredini R, Facchetti F, Invernizzi F, et al. Incidence and clinical consequences of reduced tubular phosphate re-absorption (TmPO4\/GFR) in naive chronic hepatitis B patients treated with tenofovir: a two-year field study. J Hepatol. 2013;58 Suppl 1:S316\u20137.","journal-title":"J Hepatol"},{"key":"522_CR31","doi-asserted-by":"crossref","first-page":"O90","DOI":"10.1111\/1469-0691.12220","volume":"20","author":"MC Tsai","year":"2014","unstructured":"Tsai MC, Chen CH, Hung CH, Lee CM, Chiu KW, Wang JH, et al. A comparison of efficacy and safety of 2-year telbivudine and entecavir treatment in patients with chronic hepatitis B: a match-control study. Clin Microbiol Infect. 2014;20:O90\u2013100.","journal-title":"Clin Microbiol Infect"},{"key":"522_CR32","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/jvh.12362","volume":"22","author":"E Cholongitas","year":"2015","unstructured":"Cholongitas E, Vasiliadis T, Goulis I, Fouzas I, Antoniadis N, Papanikolaou V, et al. Telbivudine is associated with improvement of renal function in patients transplanted for HBV liver disease. J Viral Hepat. 2015;22:574\u201380.","journal-title":"J Viral Hepat"},{"key":"522_CR33","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/jvh.12217","volume":"21","author":"M Lee","year":"2014","unstructured":"Lee M, Oh S, Lee HJ, Yeum TS, Lee JH, Yu SJ, et al. Telbivudine protects renal function in patients with chronic hepatitis B infection in conjunction with adefovir-based combination therapy. J Viral Hepat. 2014;21:873\u201381.","journal-title":"J Viral Hepat"},{"key":"522_CR34","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1111\/j.1365-2036.2012.05093.x","volume":"35","author":"N Gara","year":"2012","unstructured":"Gara N, Zhao X, Collins MT, Chong WH, Kleiner DE, Jake LT, et al. Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. Aliment Pharmacol Ther. 2012;35:1317\u201325.","journal-title":"Aliment Pharmacol Ther"},{"key":"522_CR35","first-page":"S24","volume":"35","author":"M Levy","year":"1991","unstructured":"Levy M, Chen N. Worldwide perspective of hepatitis B-associated glomerulonephritis in the 80s. Kidney Int Suppl. 1991;35:S24\u201333.","journal-title":"Kidney Int Suppl"},{"key":"522_CR36","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1159\/000181999","volume":"26","author":"M Levy","year":"1980","unstructured":"Levy M, Kleinknecht C. Membranous glomerulonephritis and hepatitis B virus infection. Nephron. 1980;26:259\u201365.","journal-title":"Nephron"},{"key":"522_CR37","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/BF00868249","volume":"8","author":"RD Gilbert","year":"1994","unstructured":"Gilbert RD, Wiggelinkhuizen J. The clinical course of hepatitis B virus-associated nephropathy. Pediatr Nephrol. 1994;8:11\u20134.","journal-title":"Pediatr Nephrol"},{"key":"522_CR38","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/hep.22075","volume":"47","author":"J Hou","year":"2008","unstructured":"Hou J, Yin YK, Xu D, Tan D, Niu J, Zhou X, et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1\u00a0year of a randomized, double-blind trial. Hepatology. 2008;47:447\u201354.","journal-title":"Hepatology"},{"key":"522_CR39","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/j.gastro.2008.10.026","volume":"136","author":"YF Liaw","year":"2009","unstructured":"Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, et al. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009;136:486\u201395.","journal-title":"Gastroenterology"},{"key":"522_CR40","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1471-2288-8-79","volume":"8","author":"G R\u00fccker","year":"2008","unstructured":"R\u00fccker G, Schwarzer G, Carpenter JR, Schumacher M. Undue reliance on I2 in assessing heterogeneity may mislead. BMC Med Res Methodol. 2008;8:79.","journal-title":"BMC Med Res Methodol"},{"key":"522_CR41","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12874-015-0024-z","volume":"15","author":"PT Hippel von","year":"2015","unstructured":"von Hippel PT. The heterogeneity statistic I2 can be biased in small meta-analyses. BMC Med Res Methodol. 2015;15:35.","journal-title":"BMC Med Res Methodol"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-016-0522-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T07:25:55Z","timestamp":1567754755000},"score":1,"resource":{"primary":{"URL":"http:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-016-0522-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,9]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["522"],"URL":"https:\/\/doi.org\/10.1186\/s12985-016-0522-6","relation":{},"ISSN":["1743-422X"],"issn-type":[{"type":"electronic","value":"1743-422X"}],"subject":[],"published":{"date-parts":[[2016,4,9]]},"article-number":"64"}}